Clinical trials: Metabolism and Elimination
Healthy
An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects
This is an open-label, single-dose, non-randomized study in healthy male subjects to characterize the mass balance, metabolic disposition, and identification of the metabolites and general metabolic pathways following…
- Trial name
- NCT02205905
- Testing
- 14C PER977
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Parkinson Disease
Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
This study in PD patients is designed to assess the affect food has on the absorption, distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted state and other patients following a high-fat…
- Trial name
- NCT00460148
- Testing
- Ropinirole
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Healthy
Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a…
- Trial name
- NCT03878264
- Testing
- CORT118335 Oral, 14C-CORT118335 intravenous, 14C-CORT118335 oral
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy Participants, Obesity
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
The main purposes of this study are: to investigate the safety and tolerability of ACI-19764 when it is administered to healthy participants and participants with cardiovascular risk factors to determine how quickly and to what…
- Conditions
- Healthy Participants, Obesity, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07463196
- Testing
- ACI-19764 at dose A1, ACI-19764 at dose A2, ACI-19764 at dose A3
- Where
- Netherlands
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Healthy
Absorption, Metabolism and Excretion of Dietary Polyphenolic Bioactives in Humans
The objectives of this study are to i) describe the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic parameters of selected dietary (poly)phenols in humans; and ii) to compare the ADME and…
- Trial name
- NCT03194620
- Testing
- Thearubigins, Theaflavins, Procyanidin Dimer B2 (DB2)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Neoplasm
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
This is an open-label, two-part study in participants with solid tumours and will be conducted at multiple study sites. Participants will be assessed for study eligibility prior to admission to the study site.
- Trial name
- NCT06754761
- Testing
- [14C] AZD6738, AZD6738 / ceralasertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Healthy
Study of Radiolabeled ALXN2050 in Healthy Adult Males
This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 ([14C])-ALXN2050 in healthy adult males.
- Trial name
- NCT04609670
- Testing
- [14C]-ALXN2050
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neoplasm Metastasis
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced…
- Trial name
- NCT00633269
- Testing
- AZD2281
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C-M503. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with…
- Trial name
- NCT06303921
- Testing
- 11C-M503 PET, Brain MRI, Amyloid PET
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Healthy Volunteer
A Phase 1 Study of Mosliciguat in Healthy, Adult Males
This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.
- Trial name
- NCT07185321
- Testing
- Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pulmovant, Inc.
Hypertension, Hypercholesterolemia
Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion
To evaluate the possible effects of atorvastatin on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in hypertensive patients, beyond those on lipid profile.
- Trial name
- NCT01126684
- Testing
- Atorvastatin
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Aristotle University Of Thessaloniki
Healthy Volunteer
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961
This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of…
- Trial name
- NCT04495140
- Testing
- [14C]PF-06882961, 50 mg, PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients
The aim of this study is to compare the short-term effects of ACEi and angiotensin II receptor blockers on cardiac and renal protection in black type 2 diabetics patients CARE-PLP is a double-arm, double-blind, randomized and…
- Trial name
- CARE-PLP (NCT04222686)
- Testing
- Perindopril Arginine, Losartan Potassium
- Where
- Cameroon
- Volunteers
- 23 people
- Sponsor
- Yaounde Central Hospital
Healthy Volunteer
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
This is a single-center, open label, multiple dose study to investigate the pharmacokinetics of RG1662 given twice daily over 28 days, and in addition, the excretion and metabolism of [13C]-labeled IV microdoses and an oral…
- Trial name
- NCT01684891
- Testing
- RG1662
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Healthy Participants
A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004
This study in healthy volunteers aims to answer these questions: Does the test medicine cause any important side effects? What are the blood levels of the test medicine and how quickly does the body get rid of it? How much of the…
- Trial name
- NCT06857695
- Testing
- AZD5004 film-coated tablet, [14C]AZD5004 Solution for Infusion, [14C]AZD5004 Oral Solution
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229
The objectives of this study are to evaluate the absolute bioavailability, and absorption and excretion of DA-1229, an IMP in clinical assessment for the treatment of T2DM. The oral and IV PK of DA-1229 will also be evaluated.
- Trial name
- NCT02267902
- Testing
- DA-1229
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Healthy Volunteer
Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125
This study is conducted to evaluate the absolute bioavailability, metabolism and elimination pathways of AQX-1125 in healthy male and female subjects.
- Trial name
- ADME (NCT03185195)
- Testing
- AQX-1125 Oral Tablet, [14C]-AQX-1125 IV, [14C]-AQX-1125 Oral Solution
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Absorption, Metabolism and Excretion in Healthy Volunteers
A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200
This is a Phase 1, open-label non-randomized, single dose study in healthy male subjects.
- Trial name
- NCT05238337
- Testing
- [14C]-PBI-200
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pyramid Biosciences